Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. (Q37851006)

24 August 2017

1 reference

title

Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. (English)

1 reference

Markus Peck-Radosavljevic

24 August 2017

1 reference

6

object named as

Markus Peck-Radosavljevic

0 references

Mark Sulkowski

1

object named as

Mark S Sulkowski

1 reference

24 August 2017

5

Pavel Ogurtsov

1 reference

24 August 2017

Curtis Cooper

2

1 reference

24 August 2017

Bela Hunyady

3

1 reference

24 August 2017

Jidong Jia

4

1 reference

24 August 2017

Mitchell L Shiffman

7

1 reference

24 August 2017

Cihan Yurdaydin

8

1 reference

24 August 2017

Olav Dalgard

9

1 reference

24 August 2017

language of work or name

English

0 references

publication date

8 March 2011

1 reference

Nature Reviews Gastroenterology & Hepatology

24 August 2017

1 reference

24 August 2017

8

1 reference

24 August 2017

4

1 reference

24 August 2017

212-223

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2011.21

24 August 2017

0 references

cites work

Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Hepatocellular carcinoma: recent trends in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Global epidemiology of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Neurobehavioral effects of interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Tolerability of treatments for viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Ribavirin: current role in the optimal clinical management of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Use of epoetin beta during combination therapy of infection with hepatitis c virus with ribavirin improves a sustained viral response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Bacterial infection and neutropenia during peginterferon plus ribavirin combination therapy in patients with chronic hepatitis C with and without baseline neutropenia in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Generalised Dermatitis Induced by Pegylated Interferon-alpha-2b in a Patient Infected with Genotype-1 Hepatitis C Virus : Presentation of a Case

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Exacerbation of oral lichen planus lesions during treatment of chronic hepatitis C with pegylated interferon and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Severe allergic eczema due to pegylated alpha-interferon may abate after switching to daily conventional alpha-interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Neuropsychiatric adverse effects of interferon-alpha: recognition and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Hepatitis C treatment for people with severe mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Depression during therapy with interferon alpha--how long should an antidepressant treatment last?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Decline in male sexual desire, function, and satisfaction during and after antiviral therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Side effects of interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Infection rates in HIV-HCV patients treated with interferon are similar to those in HCV mono-infection and not related to neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

The 5-HT3 receptor as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Colonic toxicity of administered drugs and chemicals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Chronic hepatitis C and Crohn's disease: nosocomial infection treatment with PEG-interferon plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

The spectrum of thyroid dysfunction in an Australian hepatitis C population treated with combination Interferon-alpha2beta and Ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Interferon Alpha Treatment and Thyroid Dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Autoimmunity and extrahepatic manifestations in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Interferon-alpha and autoimmune thyroid disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Hepatitis C virus and arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Autoimmune disease complicating antiviral therapy for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Accelerated decline in lung function and impaired reversibility with salbutamol in asthmatic patients with chronic hepatitis C virus infection: a 6-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Sarcoidosis after treatment with interferon-alpha: a case series and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Sarcoidosis during combined interferon alfa and ribavirin therapy in 2 patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Fatal cardiomyopathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Ophthalmologic complications in children with chronic hepatitis C treated with pegylated interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Is screening for interferon retinopathy in hepatitis C justified?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Pegylated-interferon-associated retinopathy in chronic hepatitis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Modafinil's use in combating interferon-induced fatigue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Aplastic anemia associated with interferon beta-1a

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Psychiatric complications of long-term interferon alfa therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Ischemic colitis during interferon-alpha treatment for chronic active hepatitis C

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Do thyroid abnormalities detected in patients treated for HCV-related chronic hepatitis persist?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Incidence of dysthyroidism during interferon therapy in chronic hepatitis C

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Pericarditis after therapy with interferon-alpha for chronic hepatitis C

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.21

Interferon plus ribavirin: a cautionary note.

31 March 2020

1 reference

12 December 2020

Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy.

1 reference

12 December 2020

Psoriasis and hepatitis C virus

1 reference

12 December 2020

Thyroid dysfunction (TD) among chronic hepatitis C patients with mild and severe hepatic fibrosis.

1 reference

12 December 2020

Immune thrombocytopenia during interferon-alfa therapy for renal cell carcinoma.

1 reference

12 December 2020

Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms.

1 reference

12 December 2020

Effects of combined interferon alpha and ribavirin therapy on thyroid functions in patients with chronic hepatitis C.

1 reference

12 December 2020

Management of chronic hepatitis C: consensus guidelines

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRGASTRO.2011.21

1 reference

24 August 2017

1 reference